The effect of switching from teriparatide to anti-RANKL antibody on cancellous and cortical bone in ovariectomized mice
Toshinobu Omiya(The University of Tokyo), Sakae Tanaka(University of Tokyo Hospital), Masaya Nakamura(Keio University), Yuho Kadono(The University of Tokyo), Tomoka Hasegawa(Hokkaido University), Naohiro Izawa(The University of Tokyo), Jun Hirose(Kumamoto University Hospital), Norio Amizuka(Hokkaido University), Morio Matsumoto(Keio University Hospital), Takeshi Miyamoto(Kumamoto Health Science University), Hisataka Yasuda(SHOWA Medical University), Yasunori Omata(The University of Tokyo)
Cited by 12
Related Papers
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
|Proceedings of the National Academy of Sciences|1998|4.3k
Tumor Necrosis Factor α Stimulates Osteoclast Differentiation by a Mechanism Independent of the Odf/Rankl–Rank Interaction
|The Journal of Experimental Medicine|2000|1.3k
Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis<i>in Vitro</i><sup>1</sup>
|Endocrinology|1998|1.2k
DC-STAMP is essential for cell–cell fusion in osteoclasts and foreign body giant cells
|The Journal of Experimental Medicine|2005|899
Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis
|Cell Metabolism|2006|771